Overview

  • Country Isle of Man, Germany, India, United Kingdom
  • CategoryDrugs & Healthcare/ Global Genomics Ecosystem

Powering the next era of genomics through blockchain technology – protecting identity, personalizing healthcare, transforming lives.

Project stage

Only a whitepaper

Detailed description

To make the direct-to-consumer business more open, fair, and beneficial to all users, the Shivom platform uses blockchain technology to create a disruptive genomics ecosystem. It ensures data is owned by the data donors themselves. It ensures a transparent and secure bridge to organizations interested in using that data.

  • Genome data donors own their data and access rights
  • Donors gain rewards for sharing their genomic data on the blockchain by selling access rights directly to third party institutions such as pharmaceutical companies
  • Pharmaceutical companies use the Shivom platform to refine drug development
  • Shivom users have full and fine-grained control of who can access the data even after a third party institution has had access to it
  • Patients get personalized health, well-being, and lifestyle information
  • A dynamic ecosystem is created and continuously refined in which the community can identify and remove potential health roadblocks before they become serious

Problem

The cost of DNA sequencing has fallen significantly. It is anticipated that by the end of the decade it will be possible to generate a person’s entire genome for less than $100. Looking ahead further, we will see dramatically lower costs for genomic analysis services. 

This will make personalized healthcare insights accessible to almost all individuals around the globe. As recently as January 2017, the worldwide leading sequencing provider Illumina unveiled a new sequencer, the NovaSeq, that the company reports will eventually provide a whole genome for less than $100. This presents a new dawn for access to personalized and precision healthcare on a global scale.

Solution

  • Identifying the best course of care for patients with a particular condition
  • Prevention of disease in healthy individuals
  • Prediction of disease risk
  • Disease diagnosis
  • Treatment, including choice of most effective medication and dosage
  • Disease prognosis
  • Identifying new drug targets

Features

  • Decentralized blockchain ecosystem
  • Genome sequencing
  • Apps and services to be added
  • Precision medicine
Show details

Additional links

  • Token details

    • Token symbol ? Token symbol — a shorten token name. It is used during an ICO and after the coin listing at the cryptocurrency exchanges. : OMX
    • Fundrasing target ? Fundraising target — the maximum amount of funds to be raised during an ICO. When it is reached, the developers stop selling the tokens because they do not need to raise more money for the project development. : 35,000,000 USD
    • Token type ? Token type — a platform for a startup launch that influences the stability of blockchain operation, the speed of transactions and the fees. :Ethereum (ERC20)
    • Soft cap ? Soft cap — the minimum amount of funds to be raised for the project development. Sometimes when the soft cap has not been reached, the money is returned to the participants. :15,000 ETH
    • Role of token ? Role of Token — type of token depending on the opportunities it offers to its owner. Utility tokens give their owners a right to use the project services, security tokens are aimed at bringing profit, and currency tokens are a money substitute. :Utility token
    • Total supply ? Total supply — a total amount of tokens that will be released by the developers. :3,000,000,000 OMX
    • Escrow agent ? Escrow agent — a qualified agent who has the right of signature in a multisig wallet. An escrow agent participates in an ICO, monitors the financial operations of the developers and confirms their fairness. :No
    • Tokens for sale ? Tokens for sale — the number of tokens offered to the participants of an ICO. :990,000,000 OMX
    • Whitelist ? Whitelist — a list of participants, who get an opportunity to buy tokens. To be whitelisted, you need to register on time because the number of participants and the registration period are usually limited. :Whitelist Closed
    • Additional emission ? Additional emission — an additional release of tokens. It can be done once after the crowd sale or on an ongoing basis. In the projects with a limited emission there is no additional emission. :No
    • Exchange listing ? Exchange listing — an assumed date when the token will be listed at a cryptocurrency exchange. The developers usually indicate it in a roadmap and a white paper. :NA
    • Accepting currencies ? Accepting currencies — cryptocurrencies and fiat currencies that can be used for buying the project tokens. :BCH, BTC, DASH, ETH, FIAT, LSK, LTC, NEO, QTUM, USD, XMR, XRP, ZEC,
    • Can't participate ? Can't participate — the countries where it is prohibited to buy tokens. These can be countries where ICOs are prohibited altogether, or countries that have the requirements that a particular project does not meet. :USA,
    • Know Your Customer (KYC) ? Know Your Customer — a verification procedure for ICO participants, during which the developers can ask for personal data, a photo and a scanned copy of a passport of a potential investor. :Yes
    Get details
  • Token and Funds Distribution

    Token distribution date

    Within 2 weeks

    Unsold tokens

    NA
      • Token Distribution

        • Funds Distribution

      Sale schedule

      Round Token Price Bonus Min / Max Purchase Soft Cap Hard Cap
      Public sale — Ended
      03 May 00:00 UTC
      10 May 00:00 UTC
      0.11 USD No - 15,000 ETH 35,000,000 USD
      Pre-sale — Ended
      16 Apr 13:00 UTC
      27 Apr 13:00 UTC
      NA No - Uncapped Uncapped
      • Team

        • Axel Schumacher photo
          Axel Schumacher
          Co-Founder & CEO
        • Gourish Singla photo
          Gourish Singla
          Co-Founder & COO
        • Sally Eaves photo
          Sally Eaves
          Co-Founder & CMO
        • Henry Ines photo
          Henry Ines
          CIO
        • Akash Gaurav photo
          Akash Gaurav
          Co-Founder & CTO
        • Natalie Pankova photo
          Natalie Pankova
          CSO
        • Rashad Ibrahim photo
          Rashad Ibrahim
          Head Of Middle East
        • Agam Kansal photo
          Agam Kansal
          VP Marketing
        • Charles Leslie photo
          Charles Leslie
          Investment Lead
        • Ajit Singh Kular photo
          Ajit Singh Kular
          Head Of Digital Marketing
        • Stephane Laurent photo
          Stephane Laurent
          Head Of Chinese Subcontinent
        • Azam Shaghaghi photo
          Azam Shaghaghi
          Head Of Public Relations
        • Ting Peng photo
          Ting Peng
          Public Relations Manager
        • Kayleen Schreiber photo
          Kayleen Schreiber
          Design Lead
        • Pierre Maarek photo
          Pierre Maarek
          Investment Lead
      • Advisors

        • David Drake
        • Ian Scarffe
          Serial Entrepreneur
        • Elie Galam
          Mathematician and Alternative Investments Expert

      Roadmap

      • Q1 2017

        Conceptualization

      • Q1-Q3 2017

        Seed round

      • Q3-Q4 2017

        Shivom Roadshow starts

      • Q1 2018

        Private round raised from major crypto vc's

      • Q1-Q2 2018
        • Innovation council
        • Partnership with state of AP
      • Q2 2018
        • Omix tokens distributed
        • Project Gaia (Partnerships for sequencing pilots globally - starting with biggest cancer hospital in AP)
        • Beta version platform product launch
      • Q2-Q3 2018

        Establishment of sequencing processes and protocols

      • Q3 2018
        • Blockchain protocols for multiple encryption
        • Co-development of new SNP panels for rare/complex disease
        • Web marketplace open
        • First Genomics lab setup
        • Shivom foundation
      • Q3-Q4 2018

        Worldwide rollout of Shivom platform

      • Q4 2018

        Formation Shivom research division

      • Q4 2018 - Q1 2019

        Multi-omics integration

      • Q1 2019

        AI platform

      Activity